AMPK is highly expressed in GBM. While searching the Cancer Genome Atlas (TCGA) database for differentially expressed metabolic kinases in human cancer, we observed significantly higher expression of the AMPK α 1, β 1 and γ 1 subunits (P ≤ 10 −7 ) in GBM than in normal brain (Fig. 1a ), and in GBM relative to lower-grade glioma (LGG) ( Fig. 1b ; P ≤ 10 −14 ). Higher expression of AMPK-α 1 (P = 0.0007), AMPK-β 1 (P = 0.01), pAMPK (active phosphorylated AMPK, P = 0.003) and the AMPK substrate pACC (P = 0.01) also correlated with poor patient survival in LGG ( Fig. 1c and Supplementary Fig. 1a ), but not with GBM ( Supplementary Fig. 1b ), potentially due to higher basal expression of AMPK across all GBM relative to LGG. This is reminiscent of other genes (such as HIF1α and CREB1) that are highly expressed (sometimes uniformly) across GBM relative to LGG 29-31 , and are not prognostic but are important for GBM pathogenesis [32] [33] [34] . Biochemical analysis of human GBM and mouse high-grade glioma (HGG) 12,35 ( Fig. 1d-g Stress is integral to tumour evolution, and cancer cell survival depends on stress management. We found that cancer-associated stress chronically activates the bioenergetic sensor AMP kinase (AMPK) and, to survive, tumour cells hijack an AMPKregulated stress response pathway conserved in normal cells. Analysis of The Cancer Genome Atlas data revealed that AMPK isoforms are highly expressed in the lethal human cancer glioblastoma (GBM). We show that AMPK inhibition reduces viability of patient-derived GBM stem cells (GSCs) and tumours. In stressed (exercised) skeletal muscle, AMPK is activated to cooperate with CREB1 (cAMP response element binding protein-1) and promote glucose metabolism. We demonstrate that oncogenic stress chronically activates AMPK in GSCs that coopt the AMPK-CREB1 pathway to coordinate tumour bioenergetics through the transcription factors HIF1α and GABPA. Finally, we show that adult mice tolerate systemic deletion of AMPK, supporting the use of AMPK pharmacological inhibitors in the treatment of GBM.
T he serine-threonine kinase AMPK is a heterotrimeric protein complex of catalytic α and regulatory β and γ subunits [1] [2] [3] . All AMPK subunits are required for AMPK stability and activity 4 . At lower cellular energy states, the γ subunits bind AMP/ADP and enhance AMPK activity to bring about energy homeostasis. AMP/ ADP binding also enables the upstream metabolic kinases LKB1 and CAMKKβ to phosphorylate α subunits, fully activating AMPK 5, 6 . AMPK is a metabolic hub 1-3 , yet its function in cancer cell metabolism remains undefined. AMPK inhibits biosynthetic kinases such as mammalian target of rapamycin (mTOR) and acetyl-CoA carboxylase (ACC) [7] [8] [9] . Therefore, AMPK is expected to play a suppressive role in cancer. Despite its tumour suppressive role in other cancers 10 , a potential oncogenic role of activated AMPK was alluded in astrocytic tumours of the brain 11 . Controversy surrounding its role in cancer stems in part due to the absence of genetic models and the use of non-specific pharmacological agents 12 . Contrary to early pharmacological studies [13] [14] [15] [16] , some recent genetic studies showed that in some contexts, AMPK provides survival advantage critical for tumour growth [17] [18] [19] [20] [21] [22] . In contrast, AMPKα 1 knockout enhanced glycolysis and accelerated tumourigenesis in a lymphoma mouse model 10 , demonstrating species-specific and tissue-specific effects. Glycolysis is positively regulated by HIF1α . However, the role of AMPK in glycolysis and its relation with HIF1α is unclear. HIF1α that is degraded in the presence of O 2 was found to be stabilized under normoxic condition in LKB1-deficient MEFS (where AMPK activity is reduced) 23 . In contrast, no such HIF1α stabilization was observed in AMPK-null MEFs 21 . While AMPK was found to inhibit the Warburg effect through HIF1α destabilization in mouse lymphoma 10 and reduce glycolysis in mouse acute lymphoblastic leukaemia (ALL) 24 , AMPK promoted glycolysis in mitotically stressed cells, breast tumours, skin fibroblasts and astrocytes 17, [25] [26] [27] [28] . In this study, we present a mechanism by which AMPK regulates HIF1α transcription and glycolysis in GBM. We provide evidence that through phosphorylation of CREB1, a transcription factor highly expressed in GBM, AMPK, controls HIF1α and GABPA transcription to regulate GBM bioenergetics.
and Supplementary Fig. 1c ) revealed that active (phosphorylated) AMPK is high in tumours compared to normal brain tissue, and higher in tumour cells relative to infiltrating macrophages ( Supplementary Fig. 1d,e ). Compared to normal brain, the AMPK upstream kinases CAMKKβ and LKB1 were not upregulated ( Fig. 1d ). Of the AMPK subunits, the α and β but not γ 1 were upregulated in GBM (Fig. 1d ). The high pAMPK signature was retained in primary GBM stem cell lines (GSCs) derived from fresh tumour tissue of both proneural and mesenchymal subtypes (Fig. 1h) .
In normal cells, AMPK activity is stimulated by glucose starvation and reduced by glucose feeding [1] [2] [3] . Unlike in normal human glial cells, high AMPK activity in GSCs was chronically maintained and was insensitive to glucose levels (Fig. 1i ). We questioned if high AMPK activity in these cells is due to oncogenesis-associated stress (OAS), which constitutes a variety of stress signals (such as ER stress, DNA damage response and oxidative stress) that are elicited as a coping response to oncogenic events 36 . GBM demonstrated high genotoxic and ER stress relative to normal brain cells and tissue ( Supplementary Fig. 1f-h ). Agents that mimicked OAS ( Supplementary Fig. 1i ,j) also activated AMPK ( Supplementary  Fig. 1k-m ), suggesting a link between OAS and pAMPK in GBM. Consistent with this observation, expression of oncogenic EGFR or KRAS, or reducing PTEN levels, in detached human astrocytes increased AMPK phosphorylation ( Supplementary Fig. 1n-p) .
AMPK is required for viability of patient-derived primary GSCs. We investigated whether pAMPK is merely an indicator of OAS or is necessary for the viability of GSCs. AMPK silencing by showing high expression of AMPK isoforms in GBM compared to normal brain and low-grade glioma (LGG) (n = 10 normal adult human brain versus 548 GBM and 534 LGG). The edges on the box plots indicate the first and third quartiles (25th and 75th percentiles) of the data, with the line in the middle being the median. The whiskers on the boxplots extend another 1.5× of the interquartile range (between 25-75% range of data) from the edges of the boxes, respectively. *P < 0.001. c, Kaplan-Meier survival plots of LGG patients. d, Western blot (WB) showing levels of pAMPK and AMPK pathway genes in GBM and normal human brain (NHB). e, Immunohistochemical (IHC) analysis of normal brain and GBM using pAMPK antibody. Scale bars, 100 μ m. f, Quantitation of pAMPK signal in human tissues (n = 15 GBM; 5 normal brain Supplementary Table 4 . All WB represent data from 2-3 independent repeats. Unprocessed blots are available in Supplementary Fig. 9 . Fig. 2 | AMPK is essential for viability of primary GBM lines in vitro. a, WB using pAMPK, pACC and AMPKβ 1/β 2 common antibody in AMPKβ 1-shRNAtreated GSC10 cells. b, Cell viability using AMPKβ 1 shRNA no. 2 (n = 3; *P ≤ 0.007, # P ≤ 0.001). c, GSC viability using AMPKβ 1 siRNA (n = 3; *P ≤ 0.001). Top: WB of β 1/β 2. Note that due to sequence homology, siRNAs knocked down both β 1 and β 2. d, WB of pAMPK and pACC in GSC lines expressing dominant-negative (DN) AMPKα 2. Cont., control. e, GSC viability using DN AMPK (average of two independent experiments). f, GSC viability using AMPKα 1/α 2 shRNA (n = 3; *P = 0.0004, + P = 0.0002, **P = 0.0003). Top: WB of AMPKα 1/α 2. g, WB showing CRISPR knockout of AMPKβ 1 in GSC10 cells. h, Viability of GSCs expressing AMPKβ 1 CRISPR (n = 3). Note that CRISPR transfection efficiency in GSCs is low (~ 30-40%). *P = 0.004, + P = 0.002, **P = 0.01, ++ P ≤ 0.006. i, Viability of oncogenic mouse neural stem cells (NPCs) from compound floxed mice (Ink4/Arf −/− ; Pten lox/lox with AMPKβ 1lox/ lox or AMPKβ 1 +/+ ) treated with Adeno-Cre. (n = 3; *P = 0.0006). j, Viability of established GBM serum cell lines expressing AMPKβ 1 shRNA (average of two independent experiments). NS, not significant. k, WB of GSC10 cells expressing human AMPKβ 1 shRNA with or without mouse AMPKβ 1. Note that AMPK α 1/2 subunits are unstable in the absence of β subunits. l, Viability of GSCs expressing human AMPKβ 1 shRNA with or without mouse AMPKβ 1 (average of two independent experiments). m, WB in GSCs expressing AMPKβ 2 shRNA. n, GSC viability in the presence of AMPKβ 2 shRNA (average of two independent experiments). o, Viability of GSCs expressing human AMPKβ 1 shRNA with or without mouse AMPKβ 2 (n = 3; *P ≤ 0.003, + P ≤ 0.004, NS = non-significant). p, Viability of GSCs expressing LKB1 shRNA or treated with CAMKKβ inhibitor (STO) or ATM inhibitor (KU). (n = 3; *P ≤ 0.0008; + P = 0.0004; **P = 0.0006. Top: WB showing efficiency of LKB1 shRNA. q,r, Viability of GSCs or GBM serum lines at indicated conditions (n = 3; NS = nonsignificant, *P ≤ 0.0006; + P ≤ 0.003). Error bars are mean ± s.d. Statistical significance, two-tailed t-test; n values are independent experiments. Source data are available in Supplementary Table 4 . WB represent data from two (d,g,k,m,p) or three (a,c) independent repeats. Unprocessed blots are available in Supplementary Fig. 9 . Supplementary Table 4 .
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AMPKβ 1 shRNA induced apoptosis ( Fig. 1j and Supplementary Video 1a,b). Depletion of AMPK by five independent genetic strategies (two AMPKβ 1 shRNAs; three β 1 siRNAs; dominantnegative AMPKα 2; AMPKα 1α 2 shRNAs; and AMPKβ 1 CRISPR) significantly reduced viability of primary GSC lines (by ~40-70%); normal human astrocytes (NHAs) remained relatively viable (Figs. 1k and 2a-h). Cre-mediated deletion of AMPKβ 1 also reduced viability of oncogenic mouse neural stem cells (NPCs) ( Fig. 2i ). Strikingly, viability of the long-established GBM serum lines U87, A172 and T98G remained unaffected by AMPK shRNA (Fig. 2j ). The effect of human AMPKβ 1 shRNA was specific because expression of shRNA-resistant mouse AMPKβ 1 cDNA in GSC9 and GSC10 lines rescued viability defects ( Fig. 2k,l) . Consistent with a previous report 37 , the AMPKβ 1 subunit was specifically critical for survival, because depletion of the lessexpressed β 2 subunit did not reduce pAMPK levels or induce cell death, and its overexpression failed to rescue β 1-silenced cells ( Fig. 2m-o or AMPKβ 1 shRNA. Data was normalized to β -actin (n = 3; *P ≤ 0.0003, + P ≤ 0.006, **P ≤ 0.003, ++ P ≤ 0.005, + *P ≤ 0.01, ***P ≤ 0.0002, # P = 0.001, ## P ≤ 0.009, +++ P ≤ 0.008). e-j, Extracellular acidification rate (ECAR; a measure of glycolysis) and oxygen consumption rate (OCR; a function of mitochondria) of GSCs (e,f), flank tumours (g,h) and established GBM serum lines (i,j) expressing NT or AMPKβ 1 shRNA (n = 3 in e,f,i,j and n = 12 tumours per genotype in g,h; *P = 0.003, + P = 0.0008, # P = 0.0004 in e; *P = 0.008, + P = 0.0008, # P = 0.001, $ P = 0.001 in f; **P ≤ 0.0001 in h; NS = nonsignificant in i,j. k, HPLC/mass spectrometric quantification of cellular energy levels in a GSC10 line expressing NT or AMPKβ 1 shRNA (n = 3; *P = 0.03, **P = 0.01, + P = 0.001). l,m, Lactate and citrate released in media by GSCs expressing NT or AMPKβ 1 shRNA (n = 3; *P = 0.01, + P = 0.03, # P ≤ 0.005). n, Kinetic flux analysis of U 13 C glucose by HPLC/mass spectrometry in GSCs expressing NT or AMPKβ 1 shRNA (average of two independent experiments). o, Quantification of mitochondrial (Mito) mass in GSCs expressing NT or AMPKβ 1 shRNA by PCR using β -actin and ND4 primers (n = 3; *P ≤ 0.0007). p, Quantification of mitochondrial complex activity in GSCs expressing NT or AMPKβ 1 shRNA (n = 3; *P = 0.003, + P = 0.01). q, Electron micrographs of GSC326 expressing NT or AMPKβ 1 shRNA. Scale bar, 2 μ m. r, Quantification of mitochondrial number in two GSC lines expressing NT or AMPKβ 1 shRNA (n = 10 cells per condition; *P ≤ 0.0002). Error bars ar mean ± s.d. Statistical significance, two-tailed t-test; n values represent independent experiments unless stated otherwise. Source data are available in Supplementary Table 4 .
(LKB1 and CAMKKβ ) also reduced the viability of GSC lines, consistent with the AMPK activation pathway being important for GBM ( Fig. 2p ).
AMPK activation during metabolic and oncogenic stress provides protection 36 . Yet, unexpectedly, a tumour-mimetic metabolic stress-like condition (1 mM glucose or 1% O 2 ) did not enhance death of AMPK- Supplementary Table 4 . All WB represent data from two (c,k,i) or three (a,m) independent repeats. Unprocessed blots in Supplementary Fig. 9 .
silenced GSCs beyond what occurred at the physiologically relevant 5 mM glucose level (at which our primary GSC lines are grown) ( Fig. 2q ). In fact, unlike long-established GBM serum lines, primary
GSCs remained viable under stress ( Fig. 2q,r) . Thus, stress-tolerant primary lines are reliable surrogates of the tumour in maintaining an AMPK-dependent stress adaptation mechanism for survival in vitro. 24 Supplementary Table 4 . Western blots represent data from two (h,j) or three (k) independent repeats. Unprocessed blots are available in Supplementary Fig. 9 .
AMPK is required for intracranial growth of GSC-derived tumours. To test if AMPK is necessary for tumour growth in vivo, we transplanted four primary GSC lines expressing non-target control (NT), AMPKβ 1 shRNA or AMPKα 1/α 2 shRNA into the cerebral cortex of immunocompromised mice. AMPK depletion increased survival and reduced tumour growth in all GSC lines (Fig. 3a,b and Supplementary Fig. 2a-e ), while no effect of AMPK silencing was observed in the GBM serum line U87 ( Supplementary  Fig. 2f ). Control mice (non-target shRNA) lived for 17-29 days, while mice transplanted with GSCs expressing AMPKβ 1 shRNA or AMPKα 1/α 2 shRNA either lived longer or remained tumour free (Fig. 3b,c and Supplementary Fig. 2e ). Consistent with our in vitro results, expression of a shRNA-resistant cumate-inducible mouse AMPKβ 1 completely rescued tumour growth and survival ( Fig. 3d-f and Supplementary Fig. 2g,h) . AMPK-silenced tumours showed significant residual AMPKβ 1 expression and AMPK activity at both the tumour and cellular levels ( Supplementary  Fig. 2i-k) , indicating inefficient silencing. The AMPK-silenced tumours were smaller and showed reduced proliferation and increased apoptosis compared to controls ( Fig. 3c ,g-l). We took one step further and tested whether repression of AMPK in established tumours enhances survival. Tumours were established using cells expressing both human AMPKβ 1 shRNA and cumateinduced mouse AMPKβ 1 (which is resistant to human shRNA). Withdrawal of cumate significantly increased survival of tumourbearing mice (Fig. 3m ).
GSC death occurs independent of AMPK-regulated mTOR and autophagy pathways. Cancer cell survival can be positively or negatively regulated by autophagy, depending on the context. AMPK positively regulates autophagy and, consequently, AMPK-silenced GSCs showed diminished basal autophagy and autophagy flux, as revealed by lower levels of LC3-II and P62 basally and in the presence of the autophagy inhibitor bafilomycin ( Supplementary  Fig. 3a,b ). AMPK-regulated mitophagy has a broad role in mitochondrial homeostasis and could be crucial for survival in some contexts. However, reduced autophagy is unlikely to be the cause of cell death in AMPK-silenced primary GSCs because consistent with previous studies 38, 39 , autophagy inhibition alone was insufficient to kill GSCs ( Supplementary Fig. 3c ). AMPK maintains cellular redox state 40, 41 by phosphorylating and inhibiting ACC1, which uses NADPH. In AMPK-silenced cells, hyperactivated ACC1 can deplete NADPH, causing oxidative stress and death that can be rescued by the reducing agent N-acetylcysteine (NAC) 41 . AMPK silencing raised levels of superoxide anion ( Supplementary Fig. 3d ), but neither the ACC inhibitor TOFA nor NAC rescued cell death, suggesting that superoxide is not the cause of death in primary GSC lines ( Supplementary Fig. 3e ). AMPK balances energy expenditure by inhibiting mTORC1, which can drain energy if uninhibited 8, 9 . Indeed, AMPK depletion caused a significant drop in ATP ( Supplementary Fig. 3f ). However, AMPK silencing did not increase mTORC1 activity, and, consistent with previous work 41 , the mTORC1 inhibitor rapamycin failed to protect AMPKsilenced GSCs ( Supplementary Fig. 3g ). AMPK silencing did not significantly affect the expression of stem cell markers in GSCs ( Supplementary Fig. 3h ). Considering these results, we postulated that AMPK-depleted GSCs probably died not due to energy drainage but due to a deficit in energy production.
AMPK regulates GSC bioenergetics. To gain molecular insight, we performed RNA sequencing (RNA-seq). Analysis of differential gene expression and deregulated pathways showed that bioenergetics of cellular metabolism (glycolysis and mitochondrial function) was the most significantly downregulated pathway in AMPK-depleted GSCs (Fig. 4a ). Transcriptional networks controlled by HIF1α and GABPA/NRF2 (two key transcription factors regulating glycolysis and mitochondria function, respectively [42] [43] [44] [45] [46] [47] were downregulated ( Fig. 4a and Supplementary Fig. 4a-c) , while other pathways (such as the SREBP-mediated lipid pathway, the Notch pathway, aminoglycan biosynthesis or MAP kinase scaffold activity) were upregulated in AMPK-silenced GSCs ( Supplementary Fig. 4c ). RNA and protein analysis of GSCs and tumours (Fig. 4b-d and Supplementary Fig. 4d ,e) confirmed that HIF1α , GABPA and their targets were downregulated in AMPKdepleted cells. Phosphorylation of pyruvate dehydrogenase (PDH) by the HIF1α transcriptional target pyruvate dehydrogenase kinase (PDK) was also reduced ( Supplementary Fig. 4e ). Despite downregulation of the HIF1α target Glut1, glucose import was not affected ( Supplementary Fig. 4f ), probably due to compensation by the other glucose transporter Glut3 ( Supplementary Fig. 4g ). Functional analysis using two independent AMPKβ 1 shR-NAs confirmed that both glycolysis and mitochondrial respiration were reduced in AMPK-silenced GSCs (Fig. 4e,f) and tumours (Fig. 4g,h) , but not in long-established GBM serum lines (Fig. 4i,j) . Accordingly, energy levels ( Fig. 4k ) and glucose-induced lactate and citrate production ( Fig. 4l,m) were also reduced. Kinetic flux analysis using 13 C glucose showed reduced labelling of several metabolites of glycolysis and the tricarboxylic acid (TCA) cycle in AMPK-depleted cells ( Fig. 4n and Supplementary Fig. 5a-h) . Mitochondrial DNA analysis, activity assay and electron microscopy showed reduced mitochondrial mass/number and mitochondrial complex activity in AMPK-silenced GSCs (Fig. 4o-r) . Although mechanisms are unclear, in some contexts PGC1α and SIRT1 have been shown to regulate mitochondrial biogenesis and respiration downstream of AMPK 48 . Total and acetylated PGC1α protein (a reaction regulated by the deacetylase SIRT1) remained unchanged in AMPK-silenced GSCs ( Supplementary Fig. 4h,i) . PGC1α overexpression did not rescue the mitochondrial defects of AMPK-silenced GSCs ( Supplementary Fig. 4j-l) . The SIRT1 activator SIRT1720 partially increased mitochondrial mass and oxygen consumption rate (OCR) in both WT AMPK-silenced GSCs ( Supplementary Fig. 4m ,n) perhaps through AMPK-independent mechanisms. Together, our findings indicate the presence of an AMPK-regulated transcriptional program that is important for GBM bioenergetics.
The HIF1α transcriptional program is downregulated in AMPK-silenced GSCs. Further molecular analyses showed that both steady-state and hypoxia-induced HIF1α protein levels were reduced in AMPK-silenced cells (Fig. 5a ). HIF1α transcript level, in the presence of actinomycin D, was only slightly decreased, suggesting that HIF1α transcription and not RNA stability accounts for the decrease in mRNA (Fig. 5b) . HIF1α protein levels also seemed more unstable in AMPK-silenced cells (Fig. 5c ). Single-cell smallmolecule RNA-FISH (sm-FISH) 49 revealed that HIF1α active transcription was indeed significantly diminished in AMPK-silenced cells (Fig. 5d,e ). Accordingly, HIF1α promoter activity and HIF1α DNA binding to its target genes 32, 33 were also reduced ( Fig. 5f,g) . Microvessel formation, potentially regulated by HIF1α -VEGF or other vasculogenic pathways, was also diminished in AMPKsilenced tumours (Fig. 5h,i) . Consistent with previous reports 32 , HIF1α silencing reduced GSC viability (Fig. 5j) .
The TCA cycle, which produces succinate, was downregulated in AMPK-silenced cells. Since succinate inhibits prolyl hydroxylases 50 that in turn hydroxylates and destabilizes HIF1α protein 51 , we tested if HIF1α is differentially hydroxylated in AMPK-silenced cells. More hydroxylated HIF1α was observed in AMPK-silenced GSCs, and the addition of succinate reduced HIF1α hydroxylation and increased HIF1α stability (Fig. 5k,l) . HIF2α plays diverse roles in glioma 32, 52 . We found that HIF2α is overexpressed in AMPK-knockdown GSCs, potentially to compensate (although insufficiently) for the loss of HIF1α (Fig. 5k ). Finally, inducible overexpression of non-degradable HIF1α partially rescued viability of AMPK-silenced GSCs (Fig. 5m ). Together, these results indicate that AMPK plays an important role in regulating HIF1α in GSCs.
The GABPA transcriptional program is downregulated in AMPKsilenced GSCs. Consistent with reduced levels of GABPA RNA and protein (Fig. 4c,d and Supplementary Fig. 4d,e ), GABPA binding shRNA (n = 3; *P = 0.002, + P = 0.001, # P = 0.004, $ P = 0.007, **P = 0.01, ++ P = 0.0005). d, Viability of GSCs expressing NT or CREB1 shRNA (n = 3); *P = 0.003, + P = 0.01). Top: WB of CREB1. e,f, ECAR and OCR in GSCs expressing CREB1 shRNA (n = 3; *P = 0.01, + P = 0.006). g,h, WB of pCREB1 S133 and CREB1 (loading control) in GSCs expressing NT shRNA or two independent AMPKβ 1 shRNAs. i, WB of pACC, pCREB1 and CREB1 in normal human astrocytes (NHAs) treated with AMPK activator A769662 or glucose starvation (30 min). j, IHC of pCREB S133 in tumours derived from GSCs expressing NT or AMPKβ 1 shRNA. Scale bar, 100 μ m. k, qRT-PCR analysis of GSC326 cells expressing control virus, CREB1 S133A or CREB1 S133E lentivirus (n = 3; *P = 0.01, + P ≤ 0.0003, $ P = 0.002, # P = 0.02, **P = 0.03). I, WB of HIF1α and GABPA in GSCs expressing CREB1 shRNA, CREB1 S133A and CREB1 S133E mutants. Total CREB1 and actin are also shown. m, WB of HIF1α and GABPA in tumours derived from GSCs expressing CREB1 S133A . Error bars are mean ± s.d. Statistical significance, two-tailed t-test; n values represent independent experiments. Source data are available in Supplementary Table 4 . All western blots represent data from two (i,l,m) or three (g,h) independent repeats. Unprocessed blots are shown in Supplementary Fig. 9 .
to its target genes 45, 46 was also diminished in AMPK-silenced cells (Fig. 6a) . Transcript levels and target DNA binding of NRF1 (another transcription factor important for mitochondrial function) 45 were upregulated (Fig. 6b,c) , probably to compensate (although insufficiently) for the reduction in GABPA. Transcription of genes coordinated by both NRF1 and GABPA (such as COX4, mTERF and POLRMT) either did not change or increased slightly (Fig. 6d ). GABPA transcribes TFAM, the transcription factor that critically regulates both transcription and replication of the mitochondrial genome [45] [46] [47] . Accordingly, silencing of GABPA reduced cell viability and respiration ( Fig. 6e-g) , and silencing TFAM reduced GSC viability (Fig. 6h,i) . Consistent with the role of GABPA in regulating TFAM and mitochondrial function, overexpression of GABPA or TFAM partially rescued viability defects of AMPK-silenced GSCs, indicating their function downstream of AMPK (Fig. 6j,k) . Since mitochondrial TCA cycle substrates were diminished in AMPKsilenced cells, we also tested if their replenishment rescue cell viability. Adding succinate but not pyruvate (as it is already present in the basal medium) partially rescued viability of AMPK-silenced GSCs. These results indicate that GABPA transcription is an important mechanism through which AMPK regulates GSC mitochondrial bioenergetics.
The AMPK-CREB1 axis regulates HIF1α and GABPA transcription in GSCs. We hypothesized that another transcription factor is a potential molecular link between AMPK and HIF1α /GABPA. Analysis of functional genomics data from ENCODE and Roadmap Epigenomics identified potential CREB1 binding sites in the HIF1α and GABPA promoter/enhancer regions ( Supplementary Fig. 6a,b) . Indeed, CREB1 chromatin immunoprecipitation (ChIP) showed significant CREB1 enrichment in the GABPA promoter and a potential enhancer distal to the HIF1α 3' region. Importantly, this enrichment was significantly diminished following AMPK silencing ( Fig. 7a ). Accordingly, CREB1 knockdown reduced HIF1α promoter activity, HIF1α and GABPA transcriptional target expression, cell viability and GSC bioenergetics ( Fig. 7b-f ). TCGA data analysis showed that CREB1, EP300 (which augments CREB1 activity), HIF1α , GABPA and TFAM, as well as phosphorylated CREB1 31 , are highly expressed in GBM relative to normal brain ( Supplementary  Fig. 7a-d) . Although only CREB1 is prognostic in LGG (P = 0.002) Fig. 8 | The AMPK-CReB1 transcriptional axis regulates GBM bioenergetics and tumour growth. a, ATP levels in GSCs expressing CREB1 S133A mutant (n = 3; *P = 0.001, + P = 0.008). Top: WB of pCREB1 and CREB1 in GSCs expressing Dox-inducible CREB1 S133A in the presence or absence of Dox. b, Viability of GSCs expressing CREB1 S133A or control virus (n = 3; *P = 0.002, + P = 0.005). c, Viability of GSCs expressing NT or AMPKβ 1 shRNA and overexpressing CREB1 S133E (n = 3; *P ≤ 0.002). Right: WB of pCREB1 and CREB1 in GSCs expressing Dox-inducible CREB1 S133E in the presence or absence of Dox. d, Growth of tumours expressing control virus or Dox-inducible CREB S133A in NSG mice fed with Dox-chow after tumour establishment. e, Kaplan-Meier survival data of Dox diet-fed mice with tumours expressing control virus or Dox-inducible CREB S133A (n = 6 mice per condition). f, Schematic showing the regulation of GBM bioenergetics by AMPK, which phosphorylates CREB at S133. This allows enhanced binding of CREB1 to its targets HIF1α and GABPA, which in turn augment the transcriptional program of glycolysis and mitochondrial biogenesis to regulate GBM viability and growth. Error bars are mean ± s.d. Statistical significance in these experiments (except e) was assessed using a two-tailed t-test; n values represent independent experiments. Source data are available in Supplementary Table 4 . All western blots represent data from two (a,c) independent repeats. Unprocessed blots are available in Supplementary Fig. 9 .
( Supplementary Fig. 7e ), all the genes mentioned are important for the biology of human cancer, including GBM [31] [32] [33] [34] 53 . These genes are therefore likely to be highly expressed uniformly across the large majority of GBMs compared to their variable expression in LGG, as reported for HIF1α and phosphorylated CREB1 [29] [30] [31] . Exercise-induced stress activates AMPK to enhance muscle bioenergetics, and active AMPK phosphorylates CREB1 at S133 [54] [55] [56] [57] [58] , a modification that activates CREB1 59 . We tested if this pathway is hijacked during oncogenesis-associated stress in GBM. AMPK silencing by two independent shRNAs reduced CREB1 S133 phosphorylation in human astrocytes (Fig. 7g,h) , while pharmacological or physiological AMPK activation enhanced it (Fig. 7i) . Accordingly, pCREB1 S133 staining was also diminished in AMPKβ 1-silenced tumours (Fig. 7j ). To establish a more direct link between CREB phosphorylation, HIF1α and GABPA, we either silenced CREB1 or overexpressed CREB1 S133A or CREB1 S133E in NHAs, and examined levels of HIF1α and GABPA and their downstream glycolysis and mitochondrial targets. Several glycolytic and mitochondrial targets of HIF1α and GABPA were downregulated in CREB1 S133Aexpressing cells and upregulated in CREB1 S133E -expressing cells (Fig. 7k ). Consistent with these results, CREB1 knockdown and CREB1 S133A repressed HIF1α and GABPA protein, while CREB1 S133E increased HIF1α and GABPA (Fig. 7l ). Accordingly, CREB1 S133Aexpressing tumours clearly showed reduced levels of HIF1α and GABPA protein (Fig. 7m) .
Acute AMPK activation caused nuclear enrichment of pCREB1 S133 ( Supplementary Fig. 7f,g) in vitro, and in the tumour, nuclear pCREB1 co-localized with pAMPK ( Supplementary Fig. 7h ). Lastly, overexpression of AMPK α , β and γ subunits in normal astrocytes increased CREB1 phosphorylation ( Supplementary Fig. 7i ). However, AMPKβ 1 overexpression did not significantly alter the proliferation of normal astrocytes ( Supplementary Fig. 7j) . Together, this evidence shows a direct link between active AMPK, CREB phosphorylation and HIF1α -and GABPA-regulated gene expression in GSCs. CREB1 is also phosphorylated at S133 by protein kinase A (PKA) 59 . However, AMPKβ 1 shRNA reduced CREB1 phosphorylation but not that of other PKA substrates, indicating its specificity for CREB1. Importantly, the PKA activator forskolin phosphorylated PKA substrates in both NT shRNA and AMPKβ 1 shRNA cells, but only CREB1 in NT shRNA cells ( Supplementary  Fig. 7k ). The failure of forskolin to phosphorylate CREB1 in AMPKβ 1 shRNA cells showed that AMPK plays a specific and dominant role in CREB1 phosphorylation in GBM.
To test if CREB1 S133 phosphorylation plays a critical role in GBM pathogenesis, we expressed inactive inducible phospho-mutant CREB1 S133A or phosphomimetic CREB1 S133E and examined GSC viability. CREB1 S133A reduced ATP levels and diminished viability (Fig. 8a,b) , while CREB1 S133E rescued viability defects of AMPKβ 1-silenced cells (Fig. 8c ). When transplanted in the brain, inducible expression of CREB1 S133A significantly delayed tumourigenesis and improved survival in mice (Fig. 8d,e ), indicating the significance of CREB1 S133 phosphorylation in GBM.
Systemic deletion of AMPK is tolerated in adult mice.
We found that various types of cancer-associated stress chronically activate AMPK and that GSCs hijack a stress response pathway conserved in normal cells, using it to survive. This suggests that AMPK is an appropriate target in GBM, and so the effect of deleting AMPK in GBM mouse models and the effects of whole-body AMPK inhibition to check systemic tolerance warrant investigation. We did not use compound C, the only reagent sometimes used as an AMPK inhibitor because of its nonspecificity. Remarkably, adult mice with systemic AMPK knockout did not show overt metabolic phenotype and lived a normal life span ( Supplementary Fig. 8 ) underscoring the potential use of AMPK inhibitors in the treatment of GBM and perhaps other human cancers where AMPK is activated.
Discussion
In this study, we show that oncogenesis-associated stress chronically activates the cellular energy sensor AMPK in GBM. Our results are consistent with the high expression of active AMPK in glioma and its requirement in proliferation of oncogenic mouse astroglia 11, 12, 60 . Why the established GBM serum lines remained viable and formed tumours independent of AMPK is unclear. Decades of culture could have altered the genetic, epigenetic and metabolic landscape of these lines 61 , allowing them to adapt and evolve AMPK-independent growth and survival pathways. AMPK was also found to enhance glioma cell viability by inducing lipid import in vitro 62 . While this remains a possibility in vivo, our primary GSC lines are grown in serum-free media containing only two essential fatty acids, precluding their dependence on serum-derived non-essential fatty acids in vitro. In contrast to our results, the metabolic stressor AICAR, which activates AMPK, inhibited growth of the established glioma serum line U87MG 16 . While we could not directly compare their results with ours, we and others have shown that AICAR suppresses cancer including glioma through multiple AMPK-independent mechanisms 12 . Previous pharmacological approaches are not fully reconcilable with later genetic studies, and there is more recent appreciation that AMPK can play a context-dependent function in cancer 3 . Consistent with tissue-and species-specific effects of AMPK, AMPKα 1 suppressed lymphomagenesis in a Myc mouse model 10 , while active AMPK was required for tumour growth in other models [17] [18] [19] [20] [21] [22] 41, 63 . Interestingly, in a functional metabolic screen, AMPKβ 1 was identified as a critical prostate cancer cell survival gene 37 , which together with our studies underscores a particularly important function of the AMPKβ 1-containing complex in cancer cell survival and tumour growth.
While the role of AMPK in cancer is complex 3 , several mechanisms are known by which it checks cellular growth and proliferation 8, 9, 64, 65 . In contrast, very few mechanisms are known by which it promotes survival and growth in other contexts. Through comprehensive genetic analysis, we here show a mechanism by which AMPK supports tumour bioenergetics, growth and survival in human glioblastoma. We show that by phosphorylating CREB1, which occurs abundantly in GBM 31 , AMPK enhances HIF1α and GABPA transcription to support GBM bioenergetics (Fig. 8f ). HIF1α can attenuate mitochondrial respiration through its transcriptional target PDK, which phosphorylates and inhibits PDH 66 . Therefore, HIF1α downregulation and reduced PDH phosphorylation was expected to augment mitochondrial respiration in AMPK-silenced cells. Perhaps downregulation of GABPA/TFAM, which are critical to mitochondrial transcription and replication, overrides the stimulatory effect of hypophosphorylated (active) PDH and diminishes mitochondrial function in AMPK-silenced GSCs.
The evidence that AMPK phosphorylates CREB at S133 (also a PKA site) in vitro and in vivo is strong [54] [55] [56] [57] [58] . AMPK also strongly phosphorylated a chimaeric peptide of CREB1 and ACC (a bonafide AMPK substrate) that lacked the AMPK phosphorylation site in ACC (S78), indicating specificity of AMPK for CREB1. In fact, the V max of AMPK for the CREB1 peptide is comparable to that for the ACC peptide (12.3 pmol min −1 versus 9.3 pmol min −1 ) 58 . High levels of nuclear CREB1 are expressed in GBM 31 . We speculate that the AMPKβ 1 complex, which is enriched in the nucleus 67 , phosphorylates CREB1 and potentially other nuclear targets 20 . It remains to be seen what specific role AMPK or the CREB1 transcriptional program (that can be regulated independent of AMPK) plays during the step-wise evolution of human cancer.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0126-z.
(qRT-PCR). The sequences that exhibited maximal knockdown/overexpression were used for the study. ShRNA sequences are provided in Supplementary Table 2 .
CRISPR-Cas9 gene knockout. CRISPR-Cas9 allows for specific genome disruption and replacement in a flexible and simple system resulting in high specificity and low cell toxicity. Three guide RNAs (gRNAs) were designed to knockout target sequence of the AMPKβ 1 locus. Donor and gRNAs were purchased from Blue Heron Biotech, WA, USA. The target sequences cloned into the pCas-Guide vector are provided in Supplementary Table 2 . The efficiency of the CRISPR-Cas9 was assessed by immunoblot assay.
Mass spectrometry of metabolites. Profiling of glycolysis, the TCA cycle and nucleotide metabolites was carried out by solvent extraction followed by liquid chromatography mass spectrometry (LC-MS). Cells were treated with 5 mM D-glucose ( U13 C6, CLM-1396, Cambridge Isotope) for different time points up to 90 min. Metabolites were detected using LC-tandem-quadrupole mass spectrometry. The investigators were blinded to allocation during experiments and outcome assessment.
Bioenergetics experiments. ATP quantification in GSCs (1 × 10 5 cells) was done using the ApoSENSOR ATP Luminescence Assay Kit (BioVision). ECAR and OCR were analysed using the XF e 96-Analyzer (Seahorse Biosciences) as before 12 . GSCs were attached to the wells with Cell Tak (Corning). Tumour tissues from flank xenografts were surgically harvested and one millimetre uniformly thick sections were incised using metal tissue matrices. From these brain sections, 2 mm diameter circular pieces were cut out using biopsy punches (Miltex, York, PA). Tissues of equal weight were analysed in the Seahorse analyzer as described 67 . Extracellular lactate and citrate were measured from culture supernatants using lactate and citrate assay kits (Biovision, Milpitas, CA).
Plasmids and clonings.
Mouse β 1 and β 2 open reading frames (ORFs) were purchased from Origene and subcloned into lentiviral vectors CMVTV and FCIV, respectively. Dominant-negative AMPKα 2 (a gift from R. Jones, McGuill University, Canada) was cloned into FCIV lentiviral vector 67 . PLenti-PGK-KRAS4A (G12V) cat. no. 35634 was from Addgene and pLV EGFRvIII Hygro was gifted by F. Furnari (Cancer Research, San Diego, California). For overexpression studies, genes were subcloned into the doxycycline-inducible lentiviral vector pInducer 20. Human AMPKβ 1 was also subcloned into cumate-inducible SparQ all-in-one lentivirus (gift from System Biosciences, Paolo Alto, CA). Human HIF1α (Acc no. KR710294.1), GABPA (Acc no. BC035031.2) and TFAM (Acc no. BC126366.1) were PCR amplified to add attB sites using TFAM, GABPA and HIF1α primers. Primer sequences are provided in Supplementary Table 3 .
The PCR fragments were gel purified and transferred into pDONR221 and pInducer20 using gateway recombination as above. Sequences of all clones were confirmed by Sanger sequencing at the CCHMC DNA Core.
To generate mCreb1 S133A, mutagenesis was performed on mCreb1 (Acc no. BC021649) in pCMV-SPORT6 with the Phusion Site Directed Mutagenesis Kit (Thermo Scientific, catalogue no. F-541). The open reading frame of wt mCreb1 and mCreb1 S133A was PCR amplified to add attB recombination sites using Herculase II Fusion DNA Polymerase (Agilent Technologies, catalogue no. 600675-51).
The PCR fragments were gel purified using the QIAquick Gel Extraction Kit (Qiagen, cat. no. 28704) and transferred by BP recombination reaction into pDONR221 (Invitrogen, cat. no. 12536-017) using Gateway BP Clonase II Enzyme Mix (Life Technologies, catalogue no. 11789-020) and subsequently by LR recombination reaction into pInducer20 using Gateway LR Clonase II Enzyme Mix (Life Technologies, catalogue no. 11791-020). To generate mCreb1 S133E, mutagenesis was performed directly on mCreb1 in pInducer20 using the Phusion Site Directed Mutagenesis Kit and primers 5'-AAGGAGGCCTGAGTACAGGAAAATTT-' and 5'-GAAAGGATTTCCCTTCGTTTTTGG-3'
For cloning into cumate-inducible SparQ vector, mouse AMPKβ 1 cDNA was amplified from pcMV-Sport6 mouse AMPKβ 1. Restriction sites were added by PCR using the following primers: forward 5′ -GCTAGCATGGGCAACACGAGC-3′ and reverse 5′ -GCGGCCGCTCATCATATCGGCTTGTAGAGGAGGGT-3′ . The PCR product and the recipient plasmid SparQ All-in-one Cumate Switch Vectors (System Biosciences Cat no. QM812B-1) were digested with NheI and NotI. The ligation reaction was transformed into GC10 Competent Cells (Sigma), and plasmid DNA was purified with QIAGEN Hi Speed Plasmid Midi Kit (Qiagen).
Sirt3 Flag (plasmid no. 13814) and pcDNA4 myc PGC-1α (plasmid no. 10974) were purchased from Addgene.
HIF1α promoter activity assay. Cells were seeded onto 6-well plates, cotransfected with the HRE luciferase reporter and control pSV40-Renilla (gifts from G. Huang) for 24 h. Transfection medium was washed off and cells were further incubated for 24 h. Cell extracts were analysed using the Dual-Luciferase Assay System (Promega).
Quantification of mitochondrial mass. Cells were treated with shRNA expressing viral particles and after 72 h, genomic DNA was prepared using was initiated with 0.02 mM NADH and reduction of absorbance at 340 nm was recorded with spectrophotometer before and after addition of rotenone (final concentration 2 μ g ml −1 ). Activity of complex I + III (NADH:cytochrome c reductase) was measured in 5 mM KH 2 PO 4 (pH 7.5), 5 mM MgCl 2 , 0.24 mM CoQ1, 0.5 mM KCN, 1 mg ml −1 BSA and 0.12 mM cytochrome c (oxidized form). Reaction was initiated with 0.02 mM NADH and increase of absorbance at 550 nm was recorded with spectrophotometer before and after addition of antimycin A (final concentration 2 μ g ml −1 ). Activity of complex IV (cytochrome c oxidase) was measured in 50 mM KH 2 PO 4 (pH 7.5), 2 μ g ml −1 rotenone and 0.03 mM reduced cytochrome c at 550 nm. Activity of complex V was measured in 50 mM Tris (pH 8.0), 5 mg ml −1 BSA, 20 mM MgCl 2 , 50 mM KCl, 15 μ M FCCP, 5 μ M antimycin A, 10 mM phosphoenol pyruvate, 2.5 mM ATP, 2 U ml −1 of lactate dehydrogenase and pyruvate kinase, and 0.02 mM NADH. Reaction was initiated by adding cell lysate followed by reduction of absorbance at 340 nm before and after addition of 2 μ M of oligomycin. Citrate synthase (CS) assay media contained 0.1 mM 5,5′ -dithiobis (2-nitrobenzoic acid); 3-carboxy-4-nitrophenyl disulfide (DTNB), 0.25% Triton X-100, 0.5 mM oxaloacetate, 0.31 mM acetyl CoA, 50 mM Tris-HCl, pH 8.0. CS activity was calculated by increasing absorbance at 412 nm using extinction coefficient for TNB 13.6 mM −1 × cm −1 .
RNA-seq. One microgram of total RNA from NT or AMPKβ 1 shRNA expressing GSCs was prepared three days after lentivirus transduction and was used for mRNA library preparation. Completed libraries were sequenced on an Illumina HiSeq2000 in Rapid Mode, generating 20 million or more highquality 50-base-long single end reads per sample. RNA-seq analysis was based on the TopHat/Cufflinks pipeline. Data was processed through NetWalker 69 , an application platform that allows interactive comparative analysis of most active networks and functional processes. The reference annotation used was based on the UCSC Known Genes table. This method allows accurate quantification of expression of all transcripts, known or novel. BAM files have been deposited to GEO (GSE82183). The investigators were blinded to allocation during experiments and outcome assessment.
Computational identification of putative CREB1 binding sites. Analysis of functional genomics data from ENCODE and Roadmap Epigenomics identified potential CREB1 binding sites in the HIF1α and GABPA promoter regions. Since no ChIP-seq datasets exist describing CREB1 binding in cell types relevant to this study, we devised a computational method for identifying likely CREB1 binding sites in relevant cell types proximal to HIF1α and GABPA. We first compiled datasets indicative of likely regulatory regions from ENCODE and Roadmap Epigenomics, including DNase-seq, ChIP-seq for specific transcription factors, and models combining specific histone marks into likely regulatory states 70 . We restricted our analysis to experiments performed in cell types relevant to this study: glial cell lines (U87 and NH-A), glioblastoma cell lines (D54 and M059J), neuronal (PFSK-1 and T98G) cell lines, neuronal stem cells, and cortex and ganglion eminence-derived neurospheres. We identified likely regulatory regions located within 100 kb of either gene by taking the union of the genomic coordinates covered by these datasets. Next, for each of these putative 'relevant' regulatory regions, we restricted our attention to regions containing ChIP-seq peaks for CREB1 in any cell type. The resulting regions are therefore first bound by CREB1 in at least one experiment, and second, likely regulatory regions in relevant cell types. Using this approach, we identified three regions putatively bound by CREB1: one in the promoter of GABPA and two in HIF1α regulatory regions. We designed primers to capture the centre of each CREB1 ChIP peak.
Chromatin immunoprecipitation assays (ChIP). ChIP assays were performed using 500 μ g of chromatin. Chromatin was sonicated to fragments of ~500 bp and immunoprecipitated using 1 μ g of ChIP-grade antibodies: HIF1α (NB100-134, Novus Biological), GABPA (sc-22810× , Santa Cruz Biotechnology), CREB1 (9104, Cell Signaling Technology) and with irrelevant IgG antibodies of mouse and rabbit origin and recovered using protein A/G magnetic beads (from Magna ChIP T A/G, Millipore). The precipitated DNA was amplified by real-time qPCR, using primer sets designed to amplify regions of the target genes. ChIP primer sequences are provided in Supplementary Table 3 .
Single-molecule RNA FISH. Control or AMPKβ 1 shRNA expressing GSC10 cells were grown on no. 1.5 cover glass and fixed with 3.7% formaldehyde in 1× PBS for 10 min at room temperature. Fixed cells were washed twice with 1× PBS, permeabilized with 70% EtOH for 2 h at 4 °C, then treated with wash buffer (2× SSC, 10% formamide) for 5 min at room temperature. Fixed, permeabilized cells were then hybridized to Stellaris sm FISH probes against human HIF1α conjugated with Quasar 570 dye in hybridization buffer (100 mg ml −1 dextran sulfate and 10% formamide in 2× SSC) overnight at 37 °C. Hybridized cells were washed in wash buffer 30 min at 37 °C, treated with DAPI, and mounted with Vectashield. Cells were imaged on a Nikon A1 laser scanning confocal microscope equipped with GaAsP detectors using 561 nm excitation for Quasar 570 dye and 405 nm excitation for DAPI. A 100× NA 1.45 objective was used for imaging and cells were sampled at Nyquist resolution (0.12um pixel size). Z-stacks of ~5 μ m were acquired to capture the entire cell. Total number of transcripts per cell was QIAamp DNA kit (Qiagen). mtDNA and genomic DNA were detected using ND4 and β -actin primers, respectively. PCR was used to compare fold change in total mitochondrial content.
RNA extraction and qRT-PCR. Two micrograms of total RNA (RNeasy kit, Qiagen) was used for first strand cDNA synthesis with oligo-dT primers and Superscript II Reverse Transcriptase (Invitrogen). qRT-PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems) and Quantitect primers (Qiagen) in an ABI PRISM 7900 Sequence Detection System (Applied Biosystems). Relative mRNA expression was calculated using the comparative Ct method after normalization to a loading control. Samples were run in triplicates with a primerlimited probe for the reference gene (actin or HPRT). Primers are provided in Supplementary Table 3 .
Orthotopic xenograft. All animal procedures were carried out in accordance with the Institutional Animal Care and Use Committee (IACUC)-approved protocol of Cincinnati Children's Hospital Medical Center (CCHMC; Cincinnati, OH). The study is compliant with all relevant ethical regulations regarding animal research. Animals were monitored daily by animal care personnel. For orthotopic implantation, 1 × 10 4 primary human GBM cells were stereotactically injected into the left striatum of NOD-SCID IL2Rg null mice. Both male and female mice were used. Randomization of mice for this study was not necessary. For in vivo bioluminescent imaging, luciferase-expressing cells were established by infection with plenti-CMV-luc viral particles (a gift from S. Wells, Cincinnati Children's Hospital, Ohio) and tumour growth was monitored using IVIS 200 system. Five minutes before bioluminescence imaging, mice were anaesthetized and injected (intraperitoneally) with luciferin (150 mg kg −1 ) and imaged using IVIS (Xenogen). All mice were euthanized following observation of lethargy and/or neurologic symptoms. For flank xenografts, 2 × 10 6 cells were injected subcutaneously and imaged using IVIS. These tumours were harvested for ex vivo bioenergetics experiments. In mice that required cumate injections, animals were injected with cumate (150 mg kg −1 ) from the day of orthotopic cell implantation every alternate day until animals were euthanized. The investigators were not blinded to allocation during experiments and outcome assessment.
Culture of human tumour cells from orthotopic xenografts.
Tumour cells were isolated from NT shRNA or AMPKβ 1 shRNA tumours and passaged once. Purity of human cells were determined by PCR with human and mousespecific DNAPolE and intracisternal A particle primers, respectively (not shown). Determination of lentiviral copy number was determined by PCR showed a lower AMPKβ 1 shRNA lentiviral integration compared to NT shRNA (3.15 ± 0.62 copies of NT versus 1.33 ± 0.31 copies of β 1 shRNA).
Generation of whole-body AMPK-knockout mice. AMPKα 1 −/− , α 2 lox/lox mice (BL/6; gifts from B. Viollet, INSERM, Institut Cochin, Paris, France) and Rosa26-CreER (BL/6; gift from A. Kumar (Cincinnati Chilren's Hospital, Ohio); originally from NCI), were crossed. AMPKβ 1 lox/lox mice obtained from the Sanger Center and AMPKβ 2 −/− mice that were generated in our lab (and crossed for > 10 generations with BL/6 mice) were also crossed with Rosa26-CreER mice. Mice were injected with tamoxifen (225 μ g g −1 body weight, intraperitoneal) at six months of age every day for three consecutive days. After one week, tissues were harvested (n = 2 mice pergenotype). Recombination efficiency was determined by western blot using AMPKα and AMPKβ antibodies. Body weight was recorded once a month and death records were used to generate survival plot. Randomization of mice for this study was not done. Genotyping primers are provided in Supplementary Table 3 .
Electron microscopy. Cell pellets were fixed in 3% glutaraldehyde/0.2 M sodium cacodylate buffer pH 7.4 for at least 1 h at 4 °C. After fixation, the samples were washed 3× with cacodylate buffer and post-fixed with 1% osmium tetroxide/0.2 M sodium cacodylate buffer pH 7.4. After fixation, cells were washed 2× with cacodylate buffer, followed by 1× with ddH 2 O. Samples were gently resuspended in 1.5% agarose (type IX ultra-low gelling) and centrifuged at 1,000g for 5 min and processed as described previously 68 . All images were taken using a 120 kV transmission electron microscope (Hitachi, H-7650, V01.07, Tokyo, Japan) Immunofluorescence microscopy. Tissue processing for frozen sections was done as described previously 67, 68 . Fluorescent images were taken on a Nikon AZ-100 multizoom microscope equipped with a Nikon DS-Ri1 camera. Confocal images were taken in Nikon C2 confocal microscope. pACC and IBA1 were both rabbit antibodies and so a tyramide-based signal amplification was used (tyramide amplification kit; Thermo Fisher T20932). Antibody information is provided in Supplementary Table 1 .
Mitochondrial complex activity. Cells were sonicated in 0.5 ml ice-cold 5 mM KH 2 PO 4 (pH 7.5), 1% digitonin, and then used for electron transport chain (ETC) enzyme assays. ETC enzymes were assayed at 30° C using a temperature-controlled spectrophotometer Shimadzu UV-1600. Activity of complex I (NADH:CoQ reductase) was measured in 5 mM KH 2 PO4 (pH 7.5), 5 mM MgCl 2 , 0.24 mM CoQ1, 0.5 mM KCN, 1 mg ml −1 BSA and 2.4 μ g ml −1 antimycin A. The reaction 1 nature research | reporting summary A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted All lines were routinely checked for mycoplasma every other week using mycoplasma-specific PCR. Contaminated cultures, if detected (very rarely) were discarded.
Commonly misidentified lines (See ICLAC register)
No cell lines were used that are listed in the ICLAC register. However, U87MG was shown to be misidentified (Sci. Trans. Med, 8, 354: 354re3). This cell line was only used in one experiment.
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Laboratory animals
Both male and female 6-9 months old NSG mice were used for xenogrant studies. Mixed background immunocompetent male and female were bread and neural stem cells were derived from E1.5 -E14.5 timed pregnant female mice.. Table 1 Antibodies were validated by using multiple positive and negative control tissues and cells.
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Wild animals
Both male and female mice were used.
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Methodology Sample preparation
Human primary glioblastoma lines were established from freshly resected tumors. For glucose uptake ,virus treated cells were harvested, counted and replated in glucose free medium (15 min). Cells were then treated with 2-NBDG (100uM) for 30 minutes. After incubation cells were harvested, washed with cold PBS and resuspended in 0.5 mL PBS before FACS acquisition. For Superoxide quatification, virus transduced Cells (100000) were plated in a 12-well plate and treated with MitoSOX Red (5μΜ) for 10 min at 37 °C. The cells were then washed with PBS. Following labeling cells were washed and filtered through a 70 mm Sefar Nylon Lab Pak Mesh. collected as single-cell suspensions. Stained cells were acquired in FACScan flow cytometers (BD Bioscience).
Instrument BD FACSCanto Flow Cytometer
Software BD FACSDiva
Cell population abundance No sorting involved in any experiment.
Gating strategy
For both experiments, initial cell population gating was placed on FSC v SSC (cell size v granularity). For MitoSOX Red stained cells, the resulting live P1 cell population was placed on PE channel for detection of Superoxide positive population. The unstained cells served as negative controls. This gated population was displayed as four quadrants for percent population analysis. Percent MitoSOX Red positive cells were in Q1 quadrant (exclusively PE positive cells). We also tried to detect differences between samples for DCFDA positive (FITC channel) simultaneously for cellular ROS. No data for DCFDA positive cells was presented or discussed in manuscript. For glucose uptake assay, P1 population was gated as described before with proper negative (unstained) controls. Cells were acquired in Alexa Fluor 488 channel. Shifted P2 population was analyzed as NBDG positive population. We performed analysis to examine percent cells with glucose uptake using FACSDiva software.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
